Allos Therapeutics, Inc.
11080 CirclePoint Road
Suite 200
Westminster
Colorado
80020
United States
Tel: 303-426-6262
Fax: 303-426-4731
Website: http://www.allos.com/
Email: corpcomm@allos.com
210 articles about Allos Therapeutics, Inc.
-
Allos Therapeutics, Inc. Reports Fourth Quarter and Full Year 2010 Financial Results
3/4/2011
-
Allos Therapeutics, Inc. Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of FOLOTYN in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma
3/4/2011
-
Allos Therapeutics, Inc. to Report Fourth Quarter and Full Year 2010 Results on March 3, 2011
2/17/2011
-
Journal of Clinical Oncology Publishes Allos Therapeutics, Inc.'s Results from Pivotal Phase 2 PROPEL Study of FOLOTYN(R) in Relapsed or Refractory Peripheral T-Cell Lymphoma
1/20/2011
-
Allos Therapeutics, Inc. Lays Off 13 Percent Of Workers
1/14/2011
-
Allos Therapeutics, Inc. Reports 2010 Financial Highlights and 2011 Key Business Priorities
1/11/2011
-
Allos Therapeutics, Inc.' Marketing Authorisation Application (MAA) for FOLOTYN(R) Accepted for Review by European Medicines Evaluation Agency
12/21/2010
-
Allos Therapeutics, Inc. Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference
12/20/2010
-
Allos Therapeutics, Inc. Release: New Analysis from Phase 2b Study Reinforces Favorable Survival Data Observed with FOLOTYN(R) Relative to Erlotinib in Advanced Non-Small Cell Lung Cancer
12/13/2010
-
Allos Therapeutics, Inc. Reports New Analyses of FOLOTYN(R) Data from PROPEL Trial in Relapsed or Refractory Peripheral T-Cell Lymphoma
12/6/2010
-
Allos Therapeutics, Inc. Announces FOLOTYN(R) Data to Be Presented as a Late Breaker at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology
12/1/2010
-
Allos Therapeutics, Inc. Release: New FOLOTYN(R) Data to Be Presented at the 2010 American Society of Hematology Annual Meeting
11/19/2010
-
Allos Therapeutics, Inc. Reports Third Quarter 2010 Financial Results
11/5/2010
-
Allos Therapeutics, Inc. to Report Third Quarter 2010 Financial Results on November 4, 2010
10/27/2010
-
Allon Therapeutics, Inc. Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Hodgkin Lymphoma by the European Commission (EC)
10/15/2010
-
Allos Therapeutics, Inc. Announces Presentation of Favorable Survival Data from Randomized Phase 2b Study of FOLOTYN(R) in Patients with Advanced Non-Small Cell Lung Cancer
10/11/2010
-
Allos Therapeutics, Inc. to Ring The NASDAQ Stock Market Closing Bell
10/4/2010
-
Allos Therapeutics, Inc. to Present at Upcoming Investor Conferences
9/13/2010
-
Allos Therapeutics, Inc. Announces FOLOTYN(R) Data Presentation at the 35th ESMO Congress
9/9/2010
-
Allos Therapeutics, Inc.'s Cancer Drug, Folotyn Extends Lung Cancer Survival
7/28/2010